OncoImmunology · 2015 · 23 citations · 44 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmune CheckpointsT Cell Responses To TumorsTumor AntigensTumor-infiltrating LymphocytesCancer Immunotherapy ResistanceCd8 Positive T CellsMelanoma ImmunotherapyMelanoma RegressionMhc Class I DeficiencyMhc Class I MoleculesT-cell Responses To Tumor AntigensTumor Antigen Recognition
T cells to inhibition both by PD-1/PDL-1 engagement and by TGFβ1, two main immune regulatory mechanisms hampering the efficiency of immunotherapy in patients.
44
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Zvi G. Fridlender, Jing Sun, Samuel Kim et al. · Cancer Cell · 2009 · 3.3K citations · Full text
Medicine, Immunology, Oncology +12
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce et al. · Nature · 2001 · 2.8K citations
Life Sciences, Immunology, Oncology +12
Janis M. Taube, Robert A. Anders, Geoffrey D. Young et al. · Science Translational Medicine · 2012 · 2.1K citations
Life Sciences, Immunology, Oncology +14